<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-7 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-7</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-7</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-1.html">extraction-schema-1</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of studies comparing neoadjuvant-adjuvant immunotherapy versus adjuvant-only immunotherapy in melanoma, including clinical outcomes, immunological mechanisms, and treatment protocols.</div>
                <p><strong>Paper ID:</strong> paper-f548cd140d88decb120cea6e525961ea69ead889</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/f548cd140d88decb120cea6e525961ea69ead889" target="_blank">Neoadjuvant immune checkpoint inhibition in the management of glioblastoma: Exploring a new frontier</a></p>
                <p><strong>Paper Venue:</strong> Frontiers in Immunology</p>
                <p><strong>Paper TL;DR:</strong> The various benefits of neoadjuvant immune checkpoint inhibition such as how this approach reduces tumor burden and allows for a greater induction of an anti-tumor immune response are discussed.</p>
                <p><strong>Paper Abstract:</strong> Brain tumors are one of the leading causes of cancer related death in both the adult and pediatric patient population. Gliomas represent a cohort of brain tumors derived from glial cell lineages which include astrocytomas, oligodendrogliomas and glioblastomas (GBMs). These tumors are known to grow aggressively and have a high lethality with GBM being the most aggressive tumor in this group. Currently, few treatment options exist for GBM outside of surgical resection, radiation therapy and chemotherapy. While these measures have been shown to marginally improve patient survival, patients, especially those diagnosed with GBM, often experience a recurrence of their disease. Following disease recurrence, treatment options become more limited as additional surgical resections can pose life threatening risk to the patient, patients may be ineligible for additional radiation, and the recurrent tumor may be resistant to chemotherapy. Immune checkpoint inhibitors (ICIs) have revolutionized the field of cancer immunotherapy as many patients with cancers residing outside the central nervous system (CNS) have experienced a survival benefit from this treatment modality. It has often been observed that this survival benefit is increased following neoadjuvant administration of immune checkpoint inhibitors as tumor antigen is still present in the patient which enables a more robust anti-tumor immune response. Interestingly, results for ICI-based studies for patients with GBM have been largely disappointing which is a stark contrast from the success this treatment modality has had in non-central nervous system cancers. In this review, we will discuss the various benefits of neoadjuvant immune checkpoint inhibition such as how this approach reduces tumor burden and allows for a greater induction of an anti-tumor immune response. Additionally, we will discuss several non-CNS cancers where neoadjuvant immune checkpoint inhibition has been successful and discuss why we believe this approach may provide a survival benefit for GBM patients. We hope this manuscript will foster future studies aimed at exploring whether this approach may be beneficial for patients diagnosed with GBM.</p>
                <p><strong>Cost:</strong> 0.017</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e7.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e7.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of studies comparing neoadjuvant-adjuvant immunotherapy versus adjuvant-only immunotherapy in melanoma, including clinical outcomes, immunological mechanisms, and treatment protocols.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Song et al. (2020)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Neoadjuvant versus adjuvant immune checkpoint blockade in the treatment of clinical stage III melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Retrospective comparative analysis reporting that neoadjuvant sequencing of immune checkpoint inhibitors in clinical stage III melanoma was associated with improved 3-year distant disease-free survival and substantial pathological response rates in the neoadjuvant cohort.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Neoadjuvant versus adjuvant immune checkpoint blockade in the treatment of clinical stage III melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_name</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Retrospective comparative analysis (neoadjuvant versus adjuvant cohorts)</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_regimen</strong></td>
                            <td>Various ICI regimens used across cohorts: ipilimumab 3 or 10 mg/kg every 3 weeks; pembrolizumab 200 mg every 3 weeks; nivolumab 240 mg every 2 weeks or 480 mg every 4 weeks; combination induction ipilimumab 3 mg/kg + nivolumab 1 mg/kg every 3 weeks followed by nivolumab maintenance (240 or 480 mg). Neoadjuvant was defined as 1â€“2 cycles of ICI prior to lymph node dissection (LND) followed by continuation after surgery; adjuvant was defined as ICI given after LND.</td>
                        </tr>
                        <tr>
                            <td><strong>is_neoadjuvant_adjuvant</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>is_adjuvant_only</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Clinical stage III melanoma undergoing lymph node dissection; total n=59 (neoadjuvant n=41; adjuvant n=18). Pathologic response evaluated in 39 neoadjuvant-treated patients.</td>
                        </tr>
                        <tr>
                            <td><strong>pathological_response</strong></td>
                            <td>Neoadjuvant cohort (39 evaluated): pathologic partial response 59%, pathologic complete response 13%.</td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td>Reported: neoadjuvant sequencing was associated with an improved 3-year distant disease-free survival (DDFS) compared with adjuvant sequencing; absolute DDFS numbers not provided in the review summary.</td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_mechanisms_identified</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>tumor_microenvironment_changes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarkers_predictive</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adverse_events</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparative_advantage</strong></td>
                            <td>Neoadjuvant sequencing associated with improved 3-year DDFS and high pathological response rates (59% pPR, 13% pCR in evaluated neoadjuvant patients); neoadjuvant approach permits early assessment of pathological response and continuation of therapy after surgery.</td>
                        </tr>
                        <tr>
                            <td><strong>hypothesized_mechanism</strong></td>
                            <td>Implicit hypothesis: neoadjuvant administration preserves tumor antigen burden at time of immune checkpoint blockade, enabling stronger priming of systemic anti-tumor immunity and improved distant disease control (as discussed in the review).</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Neoadjuvant immune checkpoint inhibition in the management of glioblastoma: Exploring a new frontier', 'publication_date_yy_mm': '2023-02'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e7.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e7.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of studies comparing neoadjuvant-adjuvant immunotherapy versus adjuvant-only immunotherapy in melanoma, including clinical outcomes, immunological mechanisms, and treatment protocols.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Blank et al. (2018)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Phase Ib randomized study (reported in the review) comparing neoadjuvant versus adjuvant administration of combined ipilimumab and nivolumab in palpable (macroscopic) stage III melanoma; neoadjuvant sequencing produced high pathological response rates and expansion of tumor-resident T-cell clones compared with adjuvant sequencing.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_name</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Phase Ib randomized trial (neoadjuvant vs adjuvant sequencing), n=20</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_regimen</strong></td>
                            <td>Combined ipilimumab 3 mg/kg + nivolumab 1 mg/kg every 3 weeks: adjuvant arm received four courses starting at week 6 post-surgery; neoadjuvant arm received two courses (every 3 weeks) prior to surgery (surgery timing: after neoadjuvant doses).</td>
                        </tr>
                        <tr>
                            <td><strong>is_neoadjuvant_adjuvant</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>is_adjuvant_only</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Palpable (macroscopic) stage III melanoma, n=20 (neoadjuvant n=10; adjuvant n=10).</td>
                        </tr>
                        <tr>
                            <td><strong>pathological_response</strong></td>
                            <td>Neoadjuvant group: 9 of 10 patients had a pathological response (90%); approximately 78% reported as achieving a profound pathological response (reported in the review summary).</td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_mechanisms_identified</strong></td>
                            <td>Neoadjuvant-treated patients demonstrated expansion of tumor-resident T-cell clones compared with the adjuvant cohort, indicating intratumoral T-cell clonal expansion/priming when therapy is given prior to tumor removal.</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_microenvironment_changes</strong></td>
                            <td>Reported increased representation/expansion of tumor-resident T-cell clones in neoadjuvant patients; profound pathological responses implying major tumor regression in treated lesions.</td>
                        </tr>
                        <tr>
                            <td><strong>biomarkers_predictive</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adverse_events</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparative_advantage</strong></td>
                            <td>Neoadjuvant sequencing produced markedly higher pathological response rates and evidence of intratumoral T-cell clonal expansion relative to the adjuvant schedule; suggests improved immune priming with preoperative ICI.</td>
                        </tr>
                        <tr>
                            <td><strong>hypothesized_mechanism</strong></td>
                            <td>Authors/review propose that neoadjuvant ICI expands tumor-resident T-cell clones in situ (maintained antigen load facilitates priming/expansion), leading to systemic anti-tumor immunity superior to starting identical therapy after tumor removal.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Neoadjuvant immune checkpoint inhibition in the management of glioblastoma: Exploring a new frontier', 'publication_date_yy_mm': '2023-02'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma <em>(Rating: 2)</em></li>
                <li>Neoadjuvant versus adjuvant immune checkpoint blockade in the treatment of clinical stage III melanoma <em>(Rating: 2)</em></li>
                <li>Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma <em>(Rating: 2)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>